Topography, clinical, and genomic correlates of 5q myeloid malignancies revisited.
暂无分享,去创建一个
A. Jankowska | M. McDevitt | G. Mufti | C. O'keefe | L. Gondek | J. Maciejewski | D. Batista | A. Jerez | M. Sekeres | H. Makishima | B. Przychodzen | R. Tiu | A. Mohamedali
[1] T. Suda,et al. Faculty Opinions recommendation of A novel tumour-suppressor function for the Notch pathway in myeloid leukaemia. , 2011 .
[2] C. Steidl,et al. Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q , 2011, Leukemia.
[3] A. Aventín,et al. NPM1 Deletion Is Associated with Gross Chromosomal Rearrangements in Leukemia , 2010, PloS one.
[4] A. Tefferi,et al. WHO-defined ‘myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations , 2010, Leukemia.
[5] A. Jankowska,et al. Characterization of chromosome arm 20q abnormalities in myeloid malignancies using genome‐wide single nucleotide polymorphism array analysis , 2010, Genes, chromosomes & cancer.
[6] M. McDevitt,et al. TP53 Mutations in Myeloid Malignancies are either Homozygous or Hemizygous due to Copy Number-Neutral Loss of Heterozygosity or Deletion of 17p , 2009, Leukemia.
[7] Wei Zhang,et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. , 2009, Cancer research.
[8] P. Nguyen,et al. Myelodysplastic syndromes , 2009, Nature Reviews Disease Primers.
[9] J. Boultwood,et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays , 2008, Haematologica.
[10] J. Clohessy,et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. , 2008, Blood.
[11] C. O'keefe,et al. Chromosomal lesions and uniparental disomy detected by SNP arrays in MDS, MDS/MPD, and MDS-derived AML. , 2008, Blood.
[12] Goberdhan P Dimri,et al. The Notch Regulator MAML1 Interacts with p53 and Functions as a Coactivator* , 2007, Journal of Biological Chemistry.
[13] S. Nimer,et al. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] P. Pandolfi,et al. Role of nucleophosmin in embryonic development and tumorigenesis , 2005, Nature.
[15] Paola Fazi,et al. Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype. , 2005, The New England journal of medicine.
[16] J. Boultwood,et al. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). , 2004, Haematologica.
[17] C. Schoch,et al. Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31 , 2004, Leukemia.
[18] E. Masliah,et al. β-Synuclein Displays an Antiapoptotic p53-dependent Phenotype and Protects Neurons from 6-Hydroxydopamine-induced Caspase 3 Activation , 2003, Journal of Biological Chemistry.
[19] E. Masliah,et al. Beta-synuclein displays an antiapoptotic p53-dependent phenotype and protects neurons from 6-hydroxydopamine-induced caspase 3 activation: cross-talk with alpha-synuclein and implication for Parkinson's disease. , 2003, The Journal of biological chemistry.
[20] C. Bloomfield,et al. Pretreatment cytogenetic abnormalities are predictive of induction success, cumulative incidence of relapse, and overall survival in adult patients with de novo acute myeloid leukemia: results from Cancer and Leukemia Group B (CALGB 8461). , 2002, Blood.
[21] A. Kasprzyk,et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. , 2002, Blood.
[22] N. Zhao,et al. Transcript map and comparative analysis of the 1.5-Mb commonly deleted segment of human 5q31 in malignant myeloid diseases with a del(5q). , 2001, Genomics.
[23] J Boultwood,et al. Transcription mapping of the 5q- syndrome critical region: cloning of two novel genes and sequencing, expression, and mapping of a further six novel cDNAs. , 2000, Genomics.
[24] L. Nagarajan,et al. Deletions of chromosome 5q13.3 and 17p loci cooperate in myeloid neoplasms. , 2000, Blood.
[25] Cervera,et al. Incidence, characterization and prognostic significance of chromosomal abnormalities in 640 patients with primary myelodysplastic syndromes , 2000, British journal of haematology.
[26] M. Uesugi,et al. The α-helical FXXΦΦ motif in p53: TAF interaction and discrimination by MDM2 , 1999 .
[27] Weiya Ma,et al. Arsenic induces apoptosis through a c-Jun NH2-terminal kinase-dependent, p53-independent pathway. , 1999, Cancer research.
[28] M. Uesugi,et al. The alpha-helical FXXPhiPhi motif in p53: TAF interaction and discrimination by MDM2. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[29] K Wheatley,et al. The importance of diagnostic cytogenetics on outcome in AML: analysis of 1,612 patients entered into the MRC AML 10 trial. The Medical Research Council Adult and Children's Leukaemia Working Parties. , 1998, Blood.
[30] K. Kinzler,et al. A model for p53-induced apoptosis , 1997, Nature.
[31] V. Buckle,et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. , 1994, Genomics.
[32] R. Espinosa,et al. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.
[33] A. Henderson,et al. International Standing Committee on Human Cytogenetic Nomenclature , 1976 .